NS1

NS1 Informations sur la molécule

Nom anglais	Src homology phosphotyrosyl phosphatase 2	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	20	Alias de la cible	Protein Tyrosine Phosphatase Non-Receptor Type 11，SHP-2，PTP2C，Protein-tyrosine phosphatase 2C，PTP-2C，PTP-1D，SH-PTP3，PTPN11，Protein-Tyrosine Phosphatase 1D，SH-PTP2，EC:3.1.3.48，Noonan Syndrome 1，EC 3.1.3.48，METCDS，SHPTP2，BPTP3，JMML，SHP2，CFC，NS1，Protein Tyrosine Phosphatase， Non-Receptor Type 11，Tyrosine-Protein Phosphatase Non-Receptor Type 11
Phase de R&D la plus avancée	Phase 3 Clinical

Nom anglais	Src homology phosphotyrosyl phosphatase 2
Alias de la cible	Protein Tyrosine Phosphatase Non-Receptor Type 11，SHP-2，PTP2C，Protein-tyrosine phosphatase 2C，PTP-2C，PTP-1D，SH-PTP3，PTPN11，Protein-Tyrosine Phosphatase 1D，SH-PTP2，EC:3.1.3.48，Noonan Syndrome 1，EC 3.1.3.48，METCDS，SHPTP2，BPTP3，JMML，SHP2，CFC，NS1，Protein Tyrosine Phosphatase， Non-Receptor Type 11，Tyrosine-Protein Phosphatase Non-Receptor Type 11
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	20
Phase de R&D la plus avancée	Phase 3 Clinical

Demande de produit

NS1Contexte de la molécule

Zika virus (ZIKV) is a member of the virus family Flaviviridae and the genus Flavivirus, transmitted by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus. Its name comes from the Zika Forest of Uganda, where the virus was first isolated in 1947. Zika virus is related to dengue, yellow fever, Japanese encephalitis, and West Nile viruses. The infection, known as Zika fever, often causes no or only mild symptoms, similar to a mild form of dengue fever. It is treated by rest. Since the 1950s, it has been known to occur within a narrow equatorial belt from Africa to Asia. As of 2016, the illness cannot be prevented by drugs or vaccines. As of February 2016, there is evidence that Zika fever in pregnant women is associated with abnormal brain development in their fetuses through mother-to-child transmission of the virus, which may result in miscarriage or microcephaly.

NS1Alias de la molécule

NS1

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
JAB-3312	JAB-3312	Phase 3 Clinical	Jacobio Pharmaceuticals Co Ltd	Solid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung	Details
JAB-3068	JAB-3068	Phase 2 Clinical	Jacobio Pharmaceuticals Co Ltd, Abbvie Inc	Solid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Adenoid Cystic; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung	Details
Vociprotafib	RMC-4630; SAR-442720	Phase 2 Clinical	Sanofi, Revolution Medicines Inc	Solid tumours; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis	Details
Batoprotafib	TNO-155	Phase 2 Clinical	Novartis Pharma Ag	Solid tumours; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma	Details
GH-21	GH 21005; GH-21; HBI-2376	Phase 2 Clinical	Suzhou GenHouse pharmaceutical Co Ltd	Solid tumours; Head and Neck Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
BR-790	BR-790	Phase 2 Clinical	Jiangxi Qingfeng Pharmaceutical Industry Co Ltd	Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
BBP-398	IACS-15509; BBP-398; IACS-13909; BMS-986466	Phase 2 Clinical	Bridgebio Pharma Inc, The University Of Texas MD Anderson Cancer Center	Solid tumours; Carcinoma, Non-Small-Cell Lung	Details
Migoprotafib	RLY-1971; GDC-1971; RO-7517834; RG-6433	Phase 1 Clinical	Relay Therapeutics Inc	Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
A-380	A-380	Phase 1 Clinical	Shandong Kelun Phaemaceutical Co Ltd, Klus Pharma Inc	Neoplasms	Details
KYHY-2303	KYHY2303; KYHY-2303	Phase 1 Clinical	Jiangsu Kanion Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Hematologic Neoplasms	Details
RG-001	RG001; RG-001	Phase 1 Clinical	Shanghai Lingji Biological Technology Co Ltd	Neoplasms	Details
HS-336	HS336; HS-336	Phase 1 Clinical	Zhejiang Hisun Pharmaceutical Co Ltd	Solid tumours	Details
HMPL-415S1	HMPL-415S1	Phase 1 Clinical	Hutchison Medipharma Ltd	Solid tumours	Details
BPI-442096		Phase 1 Clinical	Betta Pharmaceuticals Co Ltd	Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
HS-10381	HS-10381	Phase 1 Clinical	Jiangsu Hansoh Pharmaceutical Group Co Ltd	Solid tumours	Details
ET-0038	ET-0038	Phase 1 Clinical	Shanghai Yituo Pharmaceutical Technology Co Ltd	Solid tumours	Details
PF-07284892	ARRY-558; PF-07284892	Phase 1 Clinical	Pfizer Inc	Solid tumours; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung	Details
ICP-189	ICP-189	Phase 1 Clinical	InnoCare Pharma Ltd	Solid tumours; Carcinoma, Non-Small-Cell Lung	Details
ERAS-601	ERAS-601	Phase 1 Clinical	Erasca Inc	Solid tumours; Leukemia, Myeloid, Acute	Details
SH-3809	SH3809	Phase 1 Clinical	Nanjing Sanhome Pharmaceutical Co Ltd	Solid tumours	Details